Welcome to our dedicated page for VOLITIONRX SEC filings (Ticker: VNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VOLITIONRX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VOLITIONRX's regulatory disclosures and financial reporting.
Jacob Vincent Micallef, Chief Scientific Officer and director of VolitionRx Ltd (VNRX), reported a Section 16 transaction dated 09/28/2025. The filing shows 5,568 shares of common stock disposed at $0.605 per share under transaction code F. The filer states these shares were retained by VolitionRx to satisfy tax withholding obligations on the settlement of 12,375 restricted stock units, and explicitly notes that no shares were sold by the reporting person or VolitionRx in that transaction.
Following the reported transaction, the reporting person beneficially owns 398,939 shares directly, plus 55,000 shares held indirectly by spouse and 38,113 shares held by Borlaug Limited (the reporting person is the controlling director of Borlaug Limited with voting and dispositive control). The form is a routine insider disclosure of ownership changes related to equity compensation tax withholding.
Ann-Louise Batchelor, Group Chief Marketing Officer of VolitionRx Ltd (VNRX), reported a transaction dated 09/28/2025 on Form 4 in which 5,604 shares of common stock were disposed of under code F at a price of $0.605 per share. The filing shows 154,282 shares beneficially owned directly after the transaction and 29,406 shares indirectly beneficially owned through her spouse.
The filing explanation states these 5,604 shares represent the portion of 11,925 restricted stock units whose shares were retained by VolitionRx and cancelled to satisfy the reporting person’s tax withholding obligations upon settlement. The form clarifies that no shares were sold by the reporting person or by VolitionRx in connection with the withholding.
VolitionRx insider filing: Michel Gaetan, the company's Chief Operating Officer and a director, reported a transaction dated 09/28/2025 reducing his direct common stock holding. The Form 4 shows a Code F disposition of 11,362 shares at $0.605, leaving 369,079 shares beneficially owned directly after the reported transaction. The filing explains these 11,362 shares represent the portion of 22,725 restricted stock units retained by VolitionRx to satisfy tax withholding upon settlement; the form states no shares were sold by the reporting person or the company in the process. The form is signed by Gaetan on 09/30/2025.
Gael Forterre, Chief Commercial Officer and reporting person for VolitionRx Ltd (VNRX), reported a transaction dated 09/28/2025 that reduced his direct common stock holdings by 5,503 shares at a price of $0.605 per share. The filing explains these 5,503 shares were retained by the issuer to satisfy tax withholding obligations upon settlement of 13,725 restricted stock units; no shares were sold by Mr. Forterre or VolitionRx. After the reported transaction he beneficially owns 160,924 shares directly, plus 5,000 shares held by his spouse and 32,500 shares managed by Armorica Partners, LLC, for which he is the managing director and sole shareholder.
Cameron John Reynolds, President and CEO and a director of VolitionRx Ltd (VNRX), reported an open-market purchase of common stock on 09/12/2025. He acquired 15,000 shares at $0.659 per share. After the transaction he directly beneficially owns 2,624,847 shares and indirectly owns 1,007,718 shares through Concord International, Inc.; an additional 34,076 shares are held indirectly by his spouse.
The Form 4 is signed on 09/15/2025. The filing notes Reynolds is majority shareholder of Concord International, Inc., sharing voting and dispositive control over those shares.
Terig Hughes, Chief Financial Officer and Director of VolitionRX Limited (VNRX), was awarded 26,143 restricted stock units (RSUs) on 08/15/2025 in lieu of cash compensation. The Form 4 shows the RSUs were granted at a price of $0 and the reporting person beneficially owned 533,770 shares following the award. The RSUs are earned in six approximately equal monthly installments beginning 09/01/2025 and, once earned, remain subject to additional time-based vesting in two installments of 13,072 units on 11/01/2025 and 13,071 units on 02/01/2026. The award is subject to continued service through each earning and vesting date and will settle into a like number of common shares upon vesting.
VolitionRX Ltd. (VNRX) reporting person Ann-Louise Batchelor was awarded 27,400 restricted stock units (RSUs) on 08/15/2025 under the companys 2015 Stock Incentive Plan in lieu of cash compensation. The RSUs are earned in six approximately equal monthly installments beginning 09/01/2025 and, once earned, remain subject to additional time-based vesting in two equal installments of 13,700 units on 11/01/2025 and 02/01/2026. Upon vesting and settlement each RSU converts into one share of common stock. The filing reports 159,886 shares beneficially owned directly after the transaction and 29,406 shares held indirectly by spouse. The award is conditioned on continued service through the applicable earning and vesting dates.
Rodney Gerard Rootsaert, a director and officer (Secretary) of VolitionRx Limited (VNRX), reported an award of 15,223 restricted stock units (RSUs) on 08/15/2025 issued in lieu of cash compensation. The RSUs were granted at $0 price and will be earned in six approximately equal monthly installments beginning 09/01/2025. Once earned, the RSUs remain subject to additional time-based vesting in two installments of 7,612 and 7,611 on 11/01/2025 and 02/01/2026, respectively.
The filing shows Mr. Rootsaert directly beneficially owns 149,233 common shares following the award and has indirect beneficial ownership of 1,007,718 shares held by Concord International, Inc., where he is a controlling director with shared voting and dispositive power.
VolitionRX Limited insider filing shows an award of restricted stock units and a separate disposal of shares by a reporting person. The reporting person, Salvatore Thomas Butera, was awarded 33,991 restricted stock units (RSUs) on 08/15/2025 in lieu of cash compensation; the RSUs are earned in six approximately equal monthly installments beginning 09/01/2025 and, once earned, remain subject to additional time-based vesting in two installments of 16,996 and 16,995 units on 11/01/2025 and 02/01/2026, respectively. The RSUs convert to common shares upon vesting and settlement. The filing also records a disposal of 99,350 shares of common stock that are jointly owned by the reporting person and his spouse. The reporting person is CEO - Volition Veterinary and a director of VolitionRX (VNRX).
VolitionRx Ltd. insider Andrew Retter, Chief Medical Officer and director, was awarded 19,524 restricted stock units (RSUs) on 08/15/2025 in lieu of cash compensation. The RSUs are scheduled to be earned in six approximately equal monthly installments beginning 09/01/2025 and, once earned, will remain subject to additional time-based vesting in two equal installments of 9,762 units on 11/01/2025 and 02/01/2026. The RSUs are contingent on the reporting persons continued service during the earning and vesting periods. After the award, the reporting person beneficially owns 151,156 shares of common stock as reported on the Form 4.